Contact Us

Please complete the form, and a representative of Intelligent Bio Solutions will contact you shortly to assist with your enquiry.

Our Locations

New York

Intelligent Bio Solutions Inc.

Floor 5, 135 W 41st St,
New York, NY 10036,
United States

info@ibs.inc

+1 646 790 5756

Office Hours

9am – 5pm Monday to Friday

Sydney

Intelligent Bio Solutions Inc.

Level 1, Suite 5,
28-40 Lord Street,
Botany, NSW, 2019
Australia

info@ibs.inc

Office Hours

9am – 5pm Monday to Friday

Cambridge

Intelligent Fingerprinting

14-17 Evolution Business Park,
Milton Road, Impington,
Cambridge, CB24 9NG,
United Kingdom

info@intelligentfingerprinting.com

+44 (0)1223 941941

Office Hours

9am – 5pm Monday to Friday

Media Contact

For media enquiries, please contact marketing@ibs.inc.

Investor Contact

Valter Pinto, Managing Director

KCSA Strategic Communications

(212) 896-1254

INBS@kcsa.com

Find more information at investors.ibs.inc.

Connect With Us

Latest News

INBS Reports Record Fiscal Q1 2027 Revenue of $1.39M

Intelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year Growth

NEW YORK, November 10, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2026. “Fiscal first quarter revenue was the highest quarterly revenue in our Company’s…

Read More »
Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance

Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance

NEW YORK, September 09, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA),  seeking regulatory clearance of its Intelligent Fingerprinting Drug Screening System (the “System”)…

Read More »
Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission

Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission

NEW YORK, September 01, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the results of its latest Method Comparison Study for its Intelligent Fingerprinting Drug Screening System (the “System”) to detect the opiate codeine. Conducted across three independent U.S….

Read More »

Sign Up

Subscribe to receive the latest news and updates from Intelligent Bio Solutions.